Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ6F8X)

• Drug Name: PF-07284892 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMQ6F8X

Molecule-Related Drug Atlas

Drug(s) Targeting Protein-tyrosine phosphatase SHP-2 (PTPN11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JAB-3312	DMNMV0D	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
TNO155	DMZ60X4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
JAB-3068	DMSGEU6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
BBP-398	DM572ZL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
SAR442720	DMTAOPC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
RLY-1971	DMUT4YZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
A380	DMXOZDP	Aggressive cancer	2A00-2F9Z	Phase 1	[8]
RG6433	DMZM06U	Aggressive cancer	2A00-2F9Z	Phase 1	[9]
NSC-87877	DMEYKXL	Discovery agent	N.A.	Patented	[10]
Dodecane-Trimethylamine	DMUPMCZ	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein-tyrosine phosphatase SHP-2 (PTPN11)	TT7WUAV	PTN11_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04800822) A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS. U.S.National Institutes of Health.
• [2] SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. Cancer Discov. 2023 Aug 4;13(8):1789-1801.
• [3] Clinical pipeline report, company report or official report of AbbVie.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT04528836) First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of Revolution Medicines.
• [7] Clinical pipeline report, company report or official report of Relay Therapeutics.
• [8] Clinical pipeline report, company report or official report of Klus Pharma
• [9] Clinical pipeline report, company report or official report of Roche
• [10] Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem. 2008 Aug 28;51(16):4948-56.
• [11] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.